calcium gluconate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
calcium gluconate: clinical details
Prescribing considerations
- Confirm the calcium salt and exact product; calcium gluconate and calcium chloride are not calcium-equivalent.
- Use appropriate venous access and monitor for extravasation.
- In severe hyperkalaemia, continue separate potassium-lowering treatment.
- Review renal function, calcium–phosphate balance, cardiac disease, urinary calculi risk, sarcoidosis and vitamin D exposure.
- Check admixture and intravenous-line compatibility.
Contraindications and cautions
- Hypersensitivity to calcium gluconate or an excipient.
- Hypercalcaemia or hypercalciuria.
- Cardiac glycoside poisoning or concurrent treatment, apart from specified immediately life-threatening circumstances.
- Product-specific ceftriaxone restrictions in newborn babies.
- For the hameln product, repeated or prolonged treatment in children or renal impairment because of aluminium exposure.
Monitoring
- Serum calcium and clinical response.
- Heart rate or ECG during intravenous administration.
- Administration site for extravasation.
- Renal function, urinary calcium where relevant, and calcium–phosphate balance in renal impairment.
- Potassium and ECG response in severe hyperkalaemia.
Clinical pharmacology
Intravenous calcium gluconate joins the endogenous circulating calcium pool. Ionised calcium is physiologically active; the remainder is mainly protein-bound or complexed with anions. Calcium is largely handled through renal filtration and tubular reabsorption, with some faecal excretion.
Formulation and product differences
- Selected products differ slightly in total calcium content and should not be assumed interchangeable.
- The hameln product is authorised for intravenous injection or infusion and has specific aluminium-exposure restrictions.
- The B. Braun product permits deep intramuscular administration in adults when intravenous administration is not possible; children should receive it intravenously only.
- Products differ in appearance specifications, excipient contribution to calcium content and approved handling instructions.
calcium gluconate preparations and strengths
Injection
Route: Parenteral
Strengths: 10%, 10% w/v
calcium gluconate interactions
The clinical team should review medicines and intravenous-line compatibility before administration.
Digoxin and other cardiac glycosides
Calcium may intensify toxicity and cause serious arrhythmias. Intravenous use is generally contraindicated except in immediately life-threatening circumstances with specialist monitoring.
Ceftriaxone
Dangerous precipitates can form. They must not be mixed or administered simultaneously, with particularly strict restrictions in newborn babies.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.